NEW ORLEANS -- Once-daily orforglipron (Foundayo) improved outcomes in adults with type 2 diabetes and inadequate glycemic control, the international ACHIEVE-5 trial showed.
In patients already taking background insulin glargine, glycemic control was improved with add-on orforglipron, with HbA1c levels dropping by 1.58%, 1.88%, and 1.82% on average with the 3-, 12-, and 36-mg doses, respectively, versus 0.79% with placebo (P<0.001 for all), reported Francesco Giorgino, MD, of the University of Bari Aldo Moro in Bari, Italy, and colleagues.
Orforglipron therapy also yielded significant weight loss across doses, with reductions of 2.6% to 5.4% in mean body weight from baseline to 40 weeks compared with a weight gain of 0.2% with placebo.
Giorgino presented the ACHIEVE-5 trial at the American Diabetes Association (ADA) annual meeting here. The study was simultaneously published in JAMA.
Importantly, there was no increase in hypoglycemia risk observed with orforglipron. Moreover, the weight loss findings accompanied insulin doses rising by 30% to 33% among orforglipron users in the study.
